CSPG4 and melanoma: Despite early reports that have associated NG2 overexpression with melanomas, more recently, increased expression of NG2 has been identified in some other types of cancer such as acute myeloid leukemia, renal cell carcinomas, pancreatic carcinomas, and triple-negative breast carcinomas59–65.